Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Xmab14045

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Withdrawn1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT02730312Phase 1Completed

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

NCT00594555Phase 2WithdrawnPrimary

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

Showing all 2 trials

Research Network

Common Treatments

  • Xmab140451
  • Imatinib Mesylate1

Active Sponsors

  • ICON Clinical Research1
  • Xencor, Inc.1
  • Novartis1
  • University of Cincinnati1

Top Investigators

Related Conditions

  • Blastic Plasmacytoid Dendritic Cell Neoplasm1
  • Acute Myelogenous Leukemia1
  • Bcell Acute Lymphoblastic Leukemia1
  • Acute Myeloid Leukemia1

Activity Timeline